BNP Paribas Financial Markets’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-52,312
| Closed | -$199K | – | 4432 |
|
|
2020
Q1 | $199K | Buy |
52,312
+32,904
| +170% | +$142K | ﹤0.01% | 2858 |
|
|
2019
Q4 | $98.8K | Buy |
19,408
+5,941
| +44% | +$31.4K | ﹤0.01% | 3297 |
|
|
2019
Q3 | $68.1K | Buy |
13,467
+4,142
| +44% | +$20.7K | ﹤0.01% | 3326 |
|
|
2019
Q2 | $57.5K | Sell |
9,325
-8,231
| -47% | -$39.7K | ﹤0.01% | 3337 |
|
|
2019
Q1 | $81.5K | Buy |
17,556
+17,529
| +64,922% | +$79.3K | ﹤0.01% | 3244 |
|
|
2018
Q4 | $113 | Sell |
27
-2,521
| -99% | -$12.8K | ﹤0.01% | 4169 |
|
|
2018
Q3 | $16K | Hold |
2,548
| – | – | ﹤0.01% | 3509 |
|
|
2018
Q2 | $20.5K | Sell |
2,548
-20,674
| -89% | -$158K | ﹤0.01% | 3484 |
|
|
2018
Q1 | $173K | Sell |
23,222
-5,891
| -20% | -$39.2K | ﹤0.01% | 2877 |
|
|
2017
Q4 | $173K | Sell |
29,113
-6,210
| -18% | -$37.7K | ﹤0.01% | 3034 |
|
|
2017
Q3 | $260K | Buy |
35,323
+14,758
| +72% | +$93.7K | ﹤0.01% | 2332 |
|
|
2017
Q2 | $140K | Buy |
20,565
+7,604
| +59% | +$56.1K | ﹤0.01% | 2646 |
|
|
2017
Q1 | $122K | Buy |
12,961
+11,860
| +1,077% | +$118K | ﹤0.01% | 2425 |
|
|
2016
Q4 | $9.51K | Sell |
1,101
-3,608
| -77% | -$26.7K | ﹤0.01% | 3482 |
|
|
2016
Q3 | $29.8K | Buy |
4,709
+2,150
| +84% | +$13K | ﹤0.01% | 2676 |
|
|
2016
Q2 | $10.8K | Buy |
+2,559
| New | +$12.4K | ﹤0.01% | 2878 |
|
|
2016
Q1 | – | Sell |
-15,354
| Closed | -$94.1K | – | 3283 |
|
|
2015
Q4 | $94.1K | Buy |
15,354
+955
| +7% | +$6.26K | ﹤0.01% | 2372 |
|
|
2015
Q3 | $82.4K | Buy |
14,399
+8,605
| +149% | +$66K | ﹤0.01% | 2510 |
|
|
2015
Q2 | $43.2K | Buy |
5,794
+4,141
| +251% | +$25.1K | ﹤0.01% | 2581 |
|
|
2015
Q1 | $9.88K | Buy |
+1,653
| New | +$10.4K | ﹤0.01% | 2751 |
|
|
2014
Q4 | – | Sell |
-4,023
| Closed | -$20.9K | – | 3550 |
|
|
2014
Q3 | $20.9K | Buy |
+4,023
| New | +$20K | ﹤0.01% | 3139 |
|
|
2014
Q2 | – | Sell |
-156
| Closed | -$551 | – | 4007 |
|
|
2014
Q1 | $551 | Sell |
156
-616
| -80% | -$3.15K | ﹤0.01% | 3018 |
|
|
2013
Q4 | $4.12K | Sell |
772
-14,883
| -95% | -$65.5K | ﹤0.01% | 3233 |
|
|
2013
Q3 | $78.6K | Sell |
15,655
-2,581
| -14% | -$14K | ﹤0.01% | 2459 |
|
|
2013
Q2 | $81.3K | Buy |
+18,236
| New | +$81.8K | ﹤0.01% | 2583 |
|
Other funds holding PGNX
BNP Paribas Financial Markets's PGNX Position: Q2 2020 in Review
BNP Paribas Financial Markets sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 52,312 shares — an estimated $199K sold.
BNP Paribas Financial Markets first reported a position in PGNX in Q2 2013 and held it in 25 quarters. The position peaked at $260K in Q3 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- BNP Paribas Financial Markets reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- BNP Paribas Financial Markets sold 52,312 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $199K.
- BNP Paribas Financial Markets first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 25 quarters.
- BNP Paribas Financial Markets's Progenics Pharmaceuticals Inc position peaked at $260K in Q3 2017.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2020, filed 6 Aug 2020.